Soliris Injection

$3,300$13,200

Soliris Injection is a first-in-class terminal complement inhibitor discovered, developed, and supplied by Ozisik Eczane. Soliris works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the pathophysiology of multiple rare diseases.

Soliris is indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Soliris is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). It is not known if Soliris injection is safe and effective in children with PNH, or gMG, or NMOSD.

Soliris Injection
Soliris Injection
SKU: N/A Category: Tags: , ,
Open chat
1
Hello 👋
Welcome to our site, if you need help simply reply to this message, we are online and ready to help.